EA201791223A1 - Процесс для управления уровнем содержания гликанов гликопротеина - Google Patents

Процесс для управления уровнем содержания гликанов гликопротеина

Info

Publication number
EA201791223A1
EA201791223A1 EA201791223A EA201791223A EA201791223A1 EA 201791223 A1 EA201791223 A1 EA 201791223A1 EA 201791223 A EA201791223 A EA 201791223A EA 201791223 A EA201791223 A EA 201791223A EA 201791223 A1 EA201791223 A1 EA 201791223A1
Authority
EA
Eurasian Patent Office
Prior art keywords
content
glycans
glycoprotein
managing
level
Prior art date
Application number
EA201791223A
Other languages
English (en)
Other versions
EA036178B1 (ru
Inventor
Дэниел Р. Лейске
Майкл Т. Тренталанж
Original Assignee
Эмджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55024253&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201791223(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эмджен Инк. filed Critical Эмджен Инк.
Publication of EA201791223A1 publication Critical patent/EA201791223A1/ru
Publication of EA036178B1 publication Critical patent/EA036178B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В настоящем изобретении предложен способ управления содержанием фукозилированных гликанов в рекомбинантном белке.
EA201791223A 2014-12-01 2015-12-01 Процесс контроля уровня содержания гликанов в составе гликопротеинов EA036178B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462085759P 2014-12-01 2014-12-01
PCT/US2015/063271 WO2016089919A1 (en) 2014-12-01 2015-12-01 Process for manipulating the level of glycan content of a glycoprotein

Publications (2)

Publication Number Publication Date
EA201791223A1 true EA201791223A1 (ru) 2017-10-31
EA036178B1 EA036178B1 (ru) 2020-10-09

Family

ID=55024253

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202091598A EA202091598A3 (ru) 2014-12-01 2015-12-01 Процесс контроля уровня содержания гликанов в составе
EA201791223A EA036178B1 (ru) 2014-12-01 2015-12-01 Процесс контроля уровня содержания гликанов в составе гликопротеинов

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA202091598A EA202091598A3 (ru) 2014-12-01 2015-12-01 Процесс контроля уровня содержания гликанов в составе

Country Status (23)

Country Link
US (5) US10167492B2 (ru)
EP (2) EP3227454B1 (ru)
JP (3) JP6698681B2 (ru)
KR (1) KR102623965B1 (ru)
CN (1) CN107109455B (ru)
AU (3) AU2015355087B2 (ru)
BR (1) BR112017011652A2 (ru)
CA (1) CA2969225C (ru)
CL (1) CL2017001369A1 (ru)
CY (1) CY1123247T1 (ru)
DK (1) DK3227454T3 (ru)
EA (2) EA202091598A3 (ru)
ES (1) ES2784503T3 (ru)
HU (1) HUE049201T2 (ru)
IL (2) IL276165B (ru)
LT (1) LT3227454T (ru)
MX (1) MX2017006997A (ru)
PL (1) PL3227454T3 (ru)
PT (1) PT3227454T (ru)
SG (2) SG10202002458PA (ru)
SI (1) SI3227454T1 (ru)
WO (1) WO2016089919A1 (ru)
ZA (2) ZA201703729B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202091598A3 (ru) 2014-12-01 2021-01-29 Эмджен Инк. Процесс контроля уровня содержания гликанов в составе
CN110418846A (zh) * 2017-03-14 2019-11-05 美国安进公司 细胞培养物中产生的抗体的总去岩藻糖基化糖型的控制
CA3054593A1 (en) * 2017-03-31 2018-10-04 Boehringer Ingelheim International Gmbh Perfusion medium
CN111373028B (zh) * 2017-11-30 2022-07-05 正大天晴药业集团南京顺欣制药有限公司 蛋白质的生产方法
KR20200135781A (ko) * 2018-03-26 2020-12-03 암젠 인크 세포 배양에서 생산된 항체의 총 비푸코실화 당형태
WO2019224333A1 (en) * 2018-05-24 2019-11-28 Ares Trading S.A. Method for controlling the afucosylation level of a glycoprotein composition
JP2021526014A (ja) 2018-06-05 2021-09-30 アムジエン・インコーポレーテツド 抗体依存性細胞貪食の調節
CA3110530A1 (en) 2018-09-11 2020-03-19 Amgen Inc. Methods of modulating antibody-dependent cell-mediated cytotoxicity
HUP1800376A2 (hu) * 2018-11-07 2020-05-28 Richter Gedeon Nyrt Sejttenyészetben elõállított rekombináns glikoprotein glikozilációs-mintázatának megváltoztatására szolgáló módszer
CN113474366A (zh) * 2018-12-31 2021-10-01 动量制药公司 产生优特克单抗的方法
EP3917951A1 (en) * 2019-01-30 2021-12-08 Amgen, Inc Aflibercept attributes and methods of characterizing and modifying thereof
EP3966246A1 (en) 2019-05-06 2022-03-16 Amgen, Inc Modulating antibody effector functions
JP2020188737A (ja) * 2019-05-23 2020-11-26 東ソー株式会社 抗体依存性細胞傷害活性が向上した抗体の製造方法
JP2022549329A (ja) 2019-09-26 2022-11-24 アムジェン インコーポレイテッド 抗体組成物を製造する方法
WO2022026451A1 (en) * 2020-07-30 2022-02-03 Amgen Inc. Cell culture media and methods of making and using the same
WO2022036275A2 (en) * 2020-08-14 2022-02-17 Bristol-Myers Squibb Company Manufacturing process for protein
MX2023004364A (es) 2020-10-15 2023-05-03 Amgen Inc Glucanos no emparejados relativos en metodos de produccion de anticuerpos.
EP4352094A1 (en) 2021-06-07 2024-04-17 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
WO2023161885A1 (en) * 2022-02-25 2023-08-31 Kashiv Biosciences, Llc A process for improving polypeptide expression in mammalian cell culture

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
ATE236249T1 (de) 1989-09-12 2003-04-15 Hoffmann La Roche Tfn-bindende proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5096816A (en) 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
AU678787B2 (en) 1992-10-23 1997-06-12 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5763223A (en) 1995-06-29 1998-06-09 Immunex Corporation DNA encoding a cytokine that induces apoptosis
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
JP2001120262A (ja) * 1999-10-26 2001-05-08 Welfide Corp 生理活性物質の産生増強方法
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
SK288131B6 (sk) 2000-05-26 2013-10-02 Bristol-Myers Squibb Company CTLA4 mutant molecule or nucleic acid molecule, vector and host vector system, host cell, CTLA4 mutant protein, method for producing and use thereof, pharmaceutical composition and regulation method
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
DE10312765A1 (de) 2003-03-21 2004-09-30 Bayer Technology Services Gmbh Vorrichtung und Verfahren zur Sterilisation flüssiger Medien mittels UV-Bestrahlung und Kurzzeiterhitzung
TWI364458B (en) * 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
US8053238B2 (en) 2005-10-31 2011-11-08 Unhwa Corporation Isolated population of plant single cells and method of preparing the same
US20070231895A1 (en) 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
EP2495308A1 (en) 2005-12-08 2012-09-05 Amgen Inc. Improved production of glycoproteins using manganese
WO2007081031A1 (ja) * 2006-01-16 2007-07-19 Hokkaido University 糖転移酵素阻害剤
US20100166741A1 (en) * 2006-07-13 2010-07-01 Genentech , Inc. Altered br-3 binding polypeptides
SI2495307T1 (en) 2006-07-13 2018-05-31 Wyeth Llc Production of the calibration factor IX with an improved glycolization pattern
FR2904558B1 (fr) * 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
JP5401319B2 (ja) 2006-11-03 2014-01-29 ワイス・エルエルシー 細胞培養における解糖阻害物質
EP2924113B1 (en) 2007-03-02 2019-04-10 Wyeth LLC Use of copper and glutamate in cell culture for production of polypeptides
CA2682472A1 (en) * 2007-03-30 2008-10-09 Centocor Ortho Biotech Inc. High expression clones of mammalian cells with fluorescent protein a or g
PT2137655E (pt) 2007-04-16 2012-09-14 Momenta Pharmaceuticals Inc Produtos de glicoproteína definidos e métodos relacionados
US20100221823A1 (en) 2007-06-11 2010-09-02 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
EP2173861B2 (en) 2007-06-15 2017-02-22 Amgen Inc. Methods of treating cell culture media for use in a bioreactor
EP2438185A4 (en) 2009-06-05 2016-10-05 Momenta Pharmaceuticals Inc METHODS FOR MODULATING FUCOSYLATION OF GLYCOPROTEINS
BR112013009275A2 (pt) 2010-10-20 2017-06-20 Morphotek Inc glicoformas de anticorpo alfa de receptor anti-folato
EA201370187A1 (ru) 2011-02-23 2013-12-30 Амген Инк. Клеточная культуральная среда для уфс воздействия и относящиеся к ней способы
CN103597073B (zh) * 2011-03-06 2019-06-07 默克雪兰诺有限公司 低岩藻糖细胞系及其应用
US9133493B2 (en) 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
ES2625045T3 (es) 2011-07-01 2017-07-18 Amgen Inc. Cultivo de células de mamífero
AR087433A1 (es) * 2011-08-08 2014-03-26 Merck Sharp & Dohme Analogos de insulina n-glicosilados
CN103946366B (zh) 2011-09-16 2017-08-11 安姆根有限公司 细胞培养物的预编程非反馈控制的连续供料
SG11201401739YA (en) 2011-10-26 2014-05-29 Amgen Inc Methods of reducing or eliminating protein modification and degradation arising from exposure to uv light
US20150119558A1 (en) * 2012-01-20 2015-04-30 Agency For Science, Technology And Research Cho-gmt recombinant protein expression
US10059770B2 (en) 2012-01-30 2018-08-28 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of a glycoprotein composition
WO2013114164A1 (en) * 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Method for obtaining glycoprotein composition with increased afucosylation content
WO2013138159A1 (en) 2012-03-15 2013-09-19 Amgen Inc. Methods of determining exposure to uv light
US10481164B2 (en) 2012-03-26 2019-11-19 Amgen Inc. Method for using light scattering in real time to directly monitor and control impurity removal in purification processes
ES2773107T3 (es) * 2012-10-05 2020-07-09 Kyowa Kirin Co Ltd Composición de proteína heterodimérica
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
MX2016001042A (es) * 2013-07-23 2017-01-05 Biocon Ltd Metodos para controlar los niveles de fucosilacion en proteinas.
KR102280638B1 (ko) 2014-02-27 2021-07-22 에프. 호프만-라 로슈 아게 재조합 당단백질 제조에서의 세포 성장 및 글리코실화의 조절
EP3215604A4 (en) * 2014-10-27 2018-07-25 Agency For Science, Technology And Research Methods of recombinant protein expression in a cell comprising reduced udp-galactose transporter activity
EA202091598A3 (ru) 2014-12-01 2021-01-29 Эмджен Инк. Процесс контроля уровня содержания гликанов в составе

Also Published As

Publication number Publication date
SI3227454T1 (sl) 2020-06-30
IL252569B (en) 2020-08-31
ZA201703729B (en) 2021-03-31
ES2784503T3 (es) 2020-09-28
AU2020202302A1 (en) 2020-04-23
JP2020124216A (ja) 2020-08-20
CA2969225A1 (en) 2016-06-09
JP7066775B2 (ja) 2022-05-13
EP3680344A1 (en) 2020-07-15
IL276165A (en) 2020-09-30
SG10202002458PA (en) 2020-04-29
US20230159974A1 (en) 2023-05-25
SG11201704351WA (en) 2017-06-29
MX2017006997A (es) 2017-10-16
IL252569A0 (en) 2017-07-31
EA202091598A2 (ru) 2020-10-30
CN107109455A (zh) 2017-08-29
KR20170083636A (ko) 2017-07-18
US20210017565A1 (en) 2021-01-21
PL3227454T3 (pl) 2020-07-27
JP2022101669A (ja) 2022-07-06
DK3227454T3 (da) 2020-04-14
ZA202006002B (en) 2022-03-30
EP3227454B1 (en) 2020-01-29
EP3227454A1 (en) 2017-10-11
CN107109455B (zh) 2022-02-18
BR112017011652A2 (pt) 2018-06-26
PT3227454T (pt) 2020-04-06
JP2017538446A (ja) 2017-12-28
CA2969225C (en) 2023-08-22
LT3227454T (lt) 2020-07-27
CL2017001369A1 (es) 2018-02-23
HUE049201T2 (hu) 2020-09-28
IL276165B (en) 2022-11-01
EA036178B1 (ru) 2020-10-09
US10167492B2 (en) 2019-01-01
AU2015355087B2 (en) 2020-04-09
AU2015355087A1 (en) 2017-06-29
AU2022200586A1 (en) 2022-02-24
US20190085370A1 (en) 2019-03-21
JP6698681B2 (ja) 2020-05-27
CY1123247T1 (el) 2021-10-29
US20170362625A1 (en) 2017-12-21
US10822630B2 (en) 2020-11-03
US20200172947A1 (en) 2020-06-04
EA202091598A3 (ru) 2021-01-29
KR102623965B1 (ko) 2024-01-11
WO2016089919A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
EA201791223A1 (ru) Процесс для управления уровнем содержания гликанов гликопротеина
HK1244185A1 (zh) 用於生成卵清蛋白的方法和組合物
EP3172443A4 (en) System and method for reinforcing reciprocating pump
DK3130671T3 (da) Ny proteindeamidase
HUE046025T2 (hu) Baktérium-alapú fehérjeszállítás
MY190747A (en) Method for producing silazane-siloxane copolymers and the use of such copolymers
EP3149176A4 (en) Methods for altering polypeptide expression
EA201692534A1 (ru) Способы лечения гипотонии
HUP1500363A2 (en) Method for increasing the galactose content of recombinant proteins
EP3153581A4 (en) Method for producing recombinant proteins using recombinant brevibacillus
SG11201609677WA (en) Method for reducing the chlorine content of organomonophosphites using dimethylaminobutane, triethylamine or triethanolamine
TWI560363B (en) Methods for controlling engines starting and stop running
DK3127917T3 (da) Fremgangsmåde til fremstilling af antistof gennem regulering af sukkerindhold i antistof
EP3378512A4 (en) MEDICAL PUMP, METHOD FOR CONTROLLING A MEDICAL PUMP AND A PROGRAM FOR CONTROLLING A MEDICAL PUMP
EA201792527A1 (ru) Лечение зуда
EP3225263A4 (en) Injection pump control method, control unit, and injection pump
IL246747A0 (en) Methods for optimizing post-translational modifications in recombinant proteins
EP3135763A4 (en) Method for improving protein expression, and composition for protein expression
TH1601000293A (th) วิธีสำหรับควบคุมระดับฟิวโคสิเลชันในโปรตีน
CL2018001809A1 (es) Control de hongos de molde blanco.
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis
EP3241908A4 (en) Method for regulating glycosylation of recombinant glycoprotein
TH1501004930A (th) วิธีการสำหรับการผลิตเอธานอลโดยการใช้รีคอมบิแนนท์ ยีสต์ (recombinant yeast)
TH1601002047A (th) องค์ประกอบสำหรับการควบคุมปรับสภาพการแสดงออกของ c9orf72
TN2014000384A1 (fr) نظام صوتي ذكي وآمن

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM